Next Generation Immunotherapy Discoveries | October 3, 2024 | New-York and virtual
ANKET® | Antibody-based NK cell Engager Therapeutics
Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma
Harnessing the power of NK cells to develop therapeutic antibodies
Collaborating with a strong network to advance our pipeline